Clinical Trial Update: Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab. [Phase 2]

View source ↗

Summary

This Phase 2 crossover trial updates safety and tolerability data for two formulations of adalimumab in rheumatoid arthritis, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Adalimumab (Humira) (adalimumab)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2014-02-20